Interest in Wegovy's Oral Form
Have you considered that a skilled chess participant might expend up to 6,000 calories during a single tournament event? This figure exceeds three times the daily energy use of an ordinary individual.
The oral variant of Novo Nordisk's weight-loss medication, Wegovy, has generated considerable excitement, as explained by Dave Moore, a Novo Nordisk executive, during a conversation with FOX Business on Friday.
This daily pill, derived from the company's injectable weight-loss treatment, received authorization from the Food and Drug Administration in December 2025 as the initial oral GLP-1 medication and became accessible in U.S. retail outlets on Monday.
Moore, serving as Novo Nordisk's executive vice president for U.S. Operations, remarked on "The Claman Countdown" that numerous individuals had refrained from treatment due to aversion to needles. With the tablet now on the market, there's evident enthusiasm and increased engagement.
Comparable Effectiveness and Accessibility
Novo Nordisk, the producer of Wegovy, stated that trials demonstrate the pill achieves weight-loss outcomes akin to those of the injection.
The drugmaker's representative elaborated that differences are minimal. This aspect fuels our enthusiasm and pride at Novo Nordisk, as individuals no longer face a dilemma or need to settle for less.
The tablet can be obtained through 70,000 pharmacies across the nation, such as prominent chains including CVS, Costco, and Good Rx.
For cash-paying consumers, the semaglutide tablet comes at a reduced cost compared to the injectable form. Insured eligible users will incur around $25 monthly, whereas those without coverage pay approximately $149 per month, as detailed by FOX Business host Liz Claman.
Moore pointed out that production expenses for both forms are nearly identical for Novo Nordisk, yet prioritizing affordability for the pill was a key focus.
